Rein Therapeutics expands Phase 2 RENEW trial of LTI-03 in IPF into UK

• Rein Therapeutics expanded its Phase 2 RENEW trial of LTI-03 in idiopathic pulmonary fibrosis into the U.K.
• No study results were presented; the update focused on trial execution and enrollment progress.
• The first U.K. patient was randomized; 16 patients have been enrolled across the study to date.
• Sites are enrolling in the U.S., Australia, and the U.K., supporting a broader international footprint for the program.
• Two additional countries are expected to be added in coming months, signaling continued scale-up of the Phase 2 development plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606110800PRIMZONEFULLFEED9735224) on June 11, 2026, and is solely responsible for the information contained therein.